Drugs / CNP-104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05104853 | Jan 2022 → Jan 2026 | primary biliary cholangitis | COUR Pharmaceutical Development Company, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-04 | Ironwood Pharmaceuticals, Inc. | Regulatory Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. ironwoodpharma.com ↗
IND for CNP-104 Accepted by FDA; Clinical Trials Planned for the End of 2021 |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNP-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05104853 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT05104853 ↗ |